Avenue Therapeutics Stock (NASDAQ:ATXI)

Forecast Ownership Financials Chart

Previous Close

$1.97

52W Range

$1.60 - $26.48

50D Avg

$2.27

200D Avg

$5.31

Market Cap

$3.84M

Avg Vol (3M)

$44.43K

Beta

-0.18

Div Yield

-

ATXI Company Profile

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

Jun 27, 2017

Website

ATXI Performance

ATXI Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-14.54M	$-8.04M	$-3.74M
Net Income	$-10.38M	$2.05M	$-3.72M
EBITDA	$-14.54M	$-8.02M	$-3.74M
Basic EPS	$-0.98	$0.94	$-3.29
Diluted EPS	$-0.98	$0.94	$-3.29

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
BDRX	Biodexa Pharmaceuticals Plc
HOTH	Hoth Therapeutics, Inc.
CFRX	ContraFect Corporation
CNSP	CNS Pharmaceuticals, Inc.
REVB	Revelation Biosciences, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
VRAX	Virax Biolabs Group Limited
ALLR	Allarity Therapeutics, Inc.
NRBO	NeuroBo Pharmaceuticals, Inc.
WINT	Windtree Therapeutics, Inc.
PALI	Palisade Bio, Inc.